U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H23N3O5.ClH
Molecular Weight 457.907
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TOPOTECAN HYDROCHLORIDE

SMILES

Cl.CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=C3N=C5C=CC(O)=C(CN(C)C)C5=C4)C2=O

InChI

InChIKey=DGHHQBMTXTWTJV-BQAIUKQQSA-N
InChI=1S/C23H23N3O5.ClH/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20;/h5-8,27,30H,4,9-11H2,1-3H3;1H/t23-;/m0./s1

HIDE SMILES / InChI

Molecular Formula C23H23N3O5
Molecular Weight 421.4458
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020671s021lbl.pdf

Topotecan, a semi-synthetic derivative of camptothecin (a plant alkaloid obtained from the Camptotheca acuminata tree), is an anti-tumor drug with topoisomerase I-inhibitory activity similar to irinotecan. DNA topoisomerases are enzymes in the cell nucleus that regulate DNA topology (3-dimensional conformation) and facilitate nuclear processes such as DNA replication, recombination, and repair. During these processes, DNA topoisomerase I creates reversible single-stranded breaks in double-stranded DNA, allowing intact single DNA strands to pass through the break and relieve the topologic constraints inherent in supercoiled DNA. The 3'-DNA terminus of the broken DNA strand binds covalently with the topoisomerase enzyme to form a catalytic intermediate called a cleavable complex. After DNA is sufficiently relaxed and the strand passage reaction is complete, DNA topoisomerase reattaches the broken DNA strands to form the unaltered topoisomers that allow transcription to proceed. Topotecan interferes with the growth of cancer cells, which are eventually destroyed. Since the growth of normal cells can be affected by the medicine, other effects may also occur. Unlike irinotecan, topotecan is found predominantly in the inactive carboxylate form at neutral pH and it is not a prodrug. Topotecan has the same mechanism of action as irinotecan and is believed to exert its cytotoxic effects during the S-phase of DNA synthesis. Topoisomerase I relieves torsional strain in DNA by inducing reversible single strand breaks. Topotecan binds to the topoisomerase I-DNA complex and prevents religation of these single strand breaks. This ternary complex interferes with the moving replication fork, which leads to the induction of replication arrest and lethal double-stranded breaks in DNA. As mammalian cells cannot efficiently repair these double strand breaks, the formation of this ternary complex eventually leads to apoptosis (programmed cell death). Topotecan mimics a DNA base pair and binds at the site of DNA cleavage by intercalating between the upstream (−1) and downstream (+1) base pairs. Intercalation displaces the downstream DNA, thus preventing religation of the cleaved strand. By specifically binding to the enzyme–substrate complex, Topotecan acts as an uncompetitive inhibitor. Topotecan is used for the treatment of advanced ovarian cancer in patients with disease that has recurred or progressed following therapy with platinum-based regimens. Also used as a second-line therapy for treatment-sensitive small cell lung cancer, as well as in combination with cisplatin for the treatment of stage IV-B, recurrent, or persistent cervical cancer not amenable to curative treatment with surgery and/or radiation therapy. Topotecan is sold under the trade name Hycamtin.

CNS Activity

Curator's Comment: freely crosses the blood-brain barrier

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1028.0 nM [IC50]
3.16 µM [IC50]
0.448 µM [IC50]
1.1 µM [IC50]
33.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
HYCAMTIN

Approved Use

HYCAMTIN for injection is a topoisomerase inhibitor indicated for: • metastatic carcinoma of the ovary after disease progression on or after initial or subsequent chemotherapy. • small cell lung cancer platinum-sensitive disease in patients who progressed after first-line chemotherapy. • combination therapy with cisplatin for Stage IV-B, recurrent, or persistent carcinoma of the cervix which is not amenable to curative treatment.

Launch Date

1996
Primary
HYCAMTIN

Approved Use

HYCAMTIN for injection is a topoisomerase inhibitor indicated for: • metastatic carcinoma of the ovary after disease progression on or after initial or subsequent chemotherapy. • small cell lung cancer platinum-sensitive disease in patients who progressed after first-line chemotherapy. • combination therapy with cisplatin for Stage IV-B, recurrent, or persistent carcinoma of the cervix which is not amenable to curative treatment.

Launch Date

1996
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
9.29 ng/mL
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
61 ng × h/mL
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
5.23 h
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
65%
TOPOTECAN plasma
Homo sapiens
Doses

Doses

DosePopulationAdverse events​
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Other AEs: Leukopenia, Leukopenia...
Other AEs:
Leukopenia (grade 1, 1 patient)
Leukopenia (grade 2, 1 patient)
Leukopenia (grade 3, 7 patients)
Leukopenia (grade 4, 2 patients)
Neutropenia (grade 2, 6 patients)
Neutropenia (grade 3, 2 patients)
Neutropenia (grade 4, 1 patient)
Thrombocytopenia (grade 1, 2 patients)
Thrombocytopenia (grade 2, 1 patient)
Thrombocytopenia (grade 3, 1 patient)
Thrombocytopenia (grade 4, 2 patients)
Anemia (grade 1, 3 patients)
Anemia (grade 2, 3 patients)
Anemia (1 patient)
Sources:
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Other AEs: Leukopenia, Leukopenia...
Other AEs:
Leukopenia (grade 1, 4 patients)
Leukopenia (grade 2, 4 patients)
Leukopenia (grade 3, 3 patients)
Leukopenia (grade 4, 1 patient)
Neutropenia (grade 1, 1 patient)
Neutropenia (grade 2, 2 patients)
Neutropenia (grade 3, 1 patient)
Neutropenia (grade 4, 1 patient)
Thrombocytopenia (grade 2, 3 patients)
Thrombocytopenia (grade 3, 2 patients)
Anemia (grade 1, 4 patients)
Anemia (grade 2, 1 patient)
Anemia (grade 3, 1 patient)
Anemia (3 patients)
Sources:
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Other AEs: Leukopenia, Leukopenia...
Other AEs:
Leukopenia (grade 3, 40.7%)
Leukopenia (grade 4, 15.9%)
Neutropenia (grade 3, 31%)
Neutropenia (grade 4, 50.4%)
Thrombocytopenia (grade 3, 17.7%)
Thrombocytopenia (grade 4, 22.1%)
Anemia (grade 3, 26.5%)
Anemia (grade 4, 2.7%)
Nausea (grade 1, 31.9%)
Nausea (grade 2, 25%)
Nausea (grade 3, 5.2%)
Alopecia (grade 1, 19.8%)
Alopecia (grade 2, 22.4%)
Alopecia (grade 3, 4.3%)
Fatigue (grade 1, 22.4%)
Fatigue (grade 2, 10.3%)
Fatigue (grade 3, 5.2%)
Vomiting (grade 1, 12.1%)
Vomiting (grade 2, 19.8%)
Vomiting (grade 3, 4.3%)
Vomiting (grade 4, 0.9%)
Diarrhea (grade 1, 19%)
Diarrhea (grade 2, 13.8%)
Diarrhea (grade 3, 1.7%)
Diarrhea (grade 4, 0.9%)
Sources:
1.5 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 1.5 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 1.5 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 859
Health Status: unhealthy
Condition: ovarian cancer | small cell lung cancer
Age Group: adult
Sex: M+F
Population Size: 859
Sources:
Other AEs: Neutropenia...
Other AEs:
Neutropenia (grade 4, 58%)
Sources:
1.5 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 1.5 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 1.5 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 862
Health Status: unhealthy
Condition: ovarian cancer | small cell lung cancer
Age Group: adult
Sex: M+F
Population Size: 862
Sources:
Other AEs: Thrombocytopenia, Anemia...
Other AEs:
Thrombocytopenia (grade 4, 20%)
Anemia (grade 3-4, 11%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Anemia 1 patient
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Leukopenia grade 1, 1 patient
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Thrombocytopenia grade 1, 2 patients
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Anemia grade 1, 3 patients
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Leukopenia grade 2, 1 patient
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Thrombocytopenia grade 2, 1 patient
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Anemia grade 2, 3 patients
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Neutropenia grade 2, 6 patients
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Thrombocytopenia grade 3, 1 patient
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Neutropenia grade 3, 2 patients
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Leukopenia grade 3, 7 patients
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Neutropenia grade 4, 1 patient
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Leukopenia grade 4, 2 patients
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Thrombocytopenia grade 4, 2 patients
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Anemia 3 patients
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Neutropenia grade 1, 1 patient
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Anemia grade 1, 4 patients
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Leukopenia grade 1, 4 patients
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Anemia grade 2, 1 patient
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Neutropenia grade 2, 2 patients
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Thrombocytopenia grade 2, 3 patients
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Leukopenia grade 2, 4 patients
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Anemia grade 3, 1 patient
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Neutropenia grade 3, 1 patient
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Thrombocytopenia grade 3, 2 patients
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Leukopenia grade 3, 3 patients
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Leukopenia grade 4, 1 patient
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Neutropenia grade 4, 1 patient
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Vomiting grade 1, 12.1%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Diarrhea grade 1, 19%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Alopecia grade 1, 19.8%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Fatigue grade 1, 22.4%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Nausea grade 1, 31.9%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Fatigue grade 2, 10.3%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Diarrhea grade 2, 13.8%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Vomiting grade 2, 19.8%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Alopecia grade 2, 22.4%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Nausea grade 2, 25%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Diarrhea grade 3, 1.7%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Thrombocytopenia grade 3, 17.7%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Anemia grade 3, 26.5%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Neutropenia grade 3, 31%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Alopecia grade 3, 4.3%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Vomiting grade 3, 4.3%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Leukopenia grade 3, 40.7%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Fatigue grade 3, 5.2%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Nausea grade 3, 5.2%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Diarrhea grade 4, 0.9%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Vomiting grade 4, 0.9%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Leukopenia grade 4, 15.9%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Anemia grade 4, 2.7%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Thrombocytopenia grade 4, 22.1%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Neutropenia grade 4, 50.4%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Neutropenia grade 4, 58%
1.5 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 1.5 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 1.5 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 859
Health Status: unhealthy
Condition: ovarian cancer | small cell lung cancer
Age Group: adult
Sex: M+F
Population Size: 859
Sources:
Anemia grade 3-4, 11%
1.5 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 1.5 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 1.5 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 862
Health Status: unhealthy
Condition: ovarian cancer | small cell lung cancer
Age Group: adult
Sex: M+F
Population Size: 862
Sources:
Thrombocytopenia grade 4, 20%
1.5 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 1.5 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 1.5 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 862
Health Status: unhealthy
Condition: ovarian cancer | small cell lung cancer
Age Group: adult
Sex: M+F
Population Size: 862
Sources:
PubMed

PubMed

TitleDatePubMed
Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells.
1999 Dec 1
The inhibitory effects of camptothecin, a topoisomerase I inhibitor, on collagen synthesis in fibroblasts from patients with systemic sclerosis.
2001
Developmental chemotherapy in advanced ovarian cancer: incorporation of topoisomerase-I inhibitors and perspective of the Gynecologic Oncology Group.
2001
ICE bioassay. Isolating in vivo complexes of enzyme to DNA.
2001
Paclitaxel-based three-drug combinations for the treatment of small cell lung cancer: a review of the Sarah Cannon Cancer Center experience.
2001 Apr
Treatment of patients with metastatic germ cell tumors relapsing after high-dose chemotherapy.
2001 Apr
New agents for induction and postremission therapy of acute myeloid leukemia.
2001 Apr
Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.
2001 Apr
Unusual potency of BN 80915, a novel fluorinated E-ring modified camptothecin, toward human colon carcinoma cells.
2001 Apr 1
Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure.
2001 Apr 1
Clinical evidence for topotecan-paclitaxel non--cross-resistance in ovarian cancer.
2001 Apr 1
A mutation in subunit B of the DNA polymerase alpha-primase complex from Novikoff hepatoma cells concomitant with a conformational change and abnormal catalytic properties of the DNA polymerase alpha-primase complex.
2001 Aug
Pharmacodynamic model of topotecan-induced time course of neutropenia.
2001 Aug
Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor.
2001 Aug
Phase I clinical trial of weekly combined topotecan and irinotecan.
2001 Aug
Clonal heterogeneity of p53 mutations in ovarian cancer.
2001 Aug
Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study.
2001 Aug 1
Clear cell carcinoma of the ovary: a remarkable case.
2001 Feb
P73a overexpression is associated with resistance to treatment with DNA-damaging agents in a human ovarian cancer cell line.
2001 Feb 1
Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy.
2001 Feb 15
Current treatment for ovarian cancer.
2001 Jan
Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
2001 Jan
Prevention of human smooth muscle cell proliferation without induction of apoptosis by the topoisomerase I inhibitor topotecan.
2001 Jan 1
Glioma cell sensitivity to topotecan: the role of p53 and topotecan-induced DNA damage.
2001 Jan 19
Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
2001 Jul
Advances in the management of epithelial ovarian cancer.
2001 Jul
Interaction between novel anticancer agents and radiation in non-small cell lung cancer cell lines.
2001 Jul
Topotecan selectively enhances the radioresponse of human small-cell lung carcinoma and glioblastoma multiforme xenografts in nude mice.
2001 Jul 1
A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors.
2001 Jul 15
Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.
2001 Jul 15
Temporary reversal by topotecan of marked insulin resistance in a patient with myelodysplastic syndrome: case report and possible mechanism for tumor necrosis factor alpha (TNF-alpha)-induced insulin resistance.
2001 Jun
Sodium phenylbutyrate induces apoptosis in human retinoblastoma Y79 cells: the effect of combined treatment with the topoisomerase I-inhibitor topotecan.
2001 Jun
Topoisomerase I inhibition with topotecan: pharmacologic and clinical issues.
2001 Mar
Development, characterization and therapy of a disseminated model of childhood neuroblastoma in SCID mice.
2001 Mar
Death receptor-independent cytochrome c release and caspase activation mediate thymidine kinase plus ganciclovir-mediated cytotoxicity in LN-18 and LN-229 human malignant glioma cells.
2001 Mar
Carrier and dose effects on the pharmacokinetics of T-0128, a camptothecin analogue-carboxymethyl dextran conjugate, in non-tumor- and tumor-bearing rats.
2001 Mar 12
Phase I pharmacokinetic trial and correlative in vitro phase II tumor kinetic study of Apomine (SR-45023A), a novel oral biphosphonate anticancer drug.
2001 May
Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study.
2001 May
Synthesis and biological evaluation of novel A-ring modified hexacyclic camptothecin analogues.
2001 May 10
[Interaction of topotecan--a DNA topoisomerase I inhibitor--with dual-stranded polydeoxyribonucleotides. II. Formation of a complex containing several DNA molecules in the presence of topotecan].
2001 May-Jun
[Interaction of topotecan--a DNA topoisomerase inhibitor--with dual-stranded polydeoxyribonucleotides. I. Dimerization of topotecan in solution].
2001 May-Jun
Advances in chemotherapy for small cell lung cancer: single-agent activity of newer agents.
2001 May-Jun
Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure.
2001 Sep 1
Patents

Sample Use Guides

Ovarian cancer and small cell lung cancer: 1.5 mg/m2 by intravenous infusion over 30 minutes daily for 5 consecutive days, starting on Day 1 of a 21-day course. Cervical cancer: 0.75 mg/m2 by intravenous infusion over 30 minutes on Days 1, 2, and 3 repeated every 21 days in combination with cisplatin 50 mg/m2 on Day 1
Route of Administration: Intravenous
In Vitro Use Guide
In DC3F hamster lung fibroblasts, 2.5 uM topotecan caused redistribution of topo I to nonnucleolar regions of the nucleus.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:35:26 GMT 2023
Edited
by admin
on Fri Dec 15 16:35:26 GMT 2023
Record UNII
956S425ZCY
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TOPOTECAN HYDROCHLORIDE
MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
USAN  
Official Name English
TOPOTECAN ACTAVIS
Brand Name English
(S)-10-((DIMETHYLAMINO)METHYL)-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLINE-3,14(4H,12H)-DIONE MONOHYDROCHLORIDE
Systematic Name English
1H-PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLINE-3,14(4H,12H)-DIONE, 10-((DIMETHYLAMINO)METHYL)-4-ETHYL-4,9-DIHYDROXY-, MONOHYDROCHLORIDE, (S)-
Common Name English
EVOTOPIN
Brand Name English
TOPOTECAN HYDROCHLORIDE [USAN]
Common Name English
SK&F S-104864-A
Code English
TOPOTECAN HYDROCHLORIDE [MI]
Common Name English
TOPOTECAN HYDROCHLORIDE [VANDF]
Common Name English
HYCAMTIN
Brand Name English
NOGITECAN HYDROCHLORIDE
JAN  
Common Name English
TOPOTECAN HYDROCHLORIDE [USP-RS]
Common Name English
TOPOTECAN (AS HYDROCHLORIDE)
Common Name English
TOPOTECAN HCL
Common Name English
TOPOTECAN HOSPIRA
Brand Name English
NOGITECAN HYDROCHLORIDE [JAN]
Common Name English
Topotecan hydrochloride [WHO-DD]
Common Name English
POTACTASOL
Brand Name English
NSC-759263
Code English
TOPOTECAN HYDROCHLORIDE [ORANGE BOOK]
Common Name English
SK&F-S-104864-A
Code English
TOPOTECAN TEVA
Brand Name English
TOPOTECAN HYDROCHLORIDE [MART.]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 268508
Created by admin on Fri Dec 15 16:35:26 GMT 2023 , Edited by admin on Fri Dec 15 16:35:26 GMT 2023
EMA ASSESSMENT REPORTS POTACTASOL (AUTHORIZED: UTERINE CERVICAL NEOPLASMS)
Created by admin on Fri Dec 15 16:35:26 GMT 2023 , Edited by admin on Fri Dec 15 16:35:26 GMT 2023
EMA ASSESSMENT REPORTS TOPOTECAN TEVA (AUTHORIZED: UTERINE CERVICAL NEOPLASMS)
Created by admin on Fri Dec 15 16:35:26 GMT 2023 , Edited by admin on Fri Dec 15 16:35:26 GMT 2023
EMA ASSESSMENT REPORTS HYCAMTIN (AUTHORIZED: UTERINE CERVICAL NEOPLASMS)
Created by admin on Fri Dec 15 16:35:26 GMT 2023 , Edited by admin on Fri Dec 15 16:35:26 GMT 2023
EMA ASSESSMENT REPORTS TOPOTECAN EAGLE (WITHDRAWN SMALL CELL LUNG CARCINOMA)
Created by admin on Fri Dec 15 16:35:26 GMT 2023 , Edited by admin on Fri Dec 15 16:35:26 GMT 2023
EMA ASSESSMENT REPORTS TOPOTECAN TEVA (AUTHORIZED: OVARIAN NEOPLASMS)
Created by admin on Fri Dec 15 16:35:26 GMT 2023 , Edited by admin on Fri Dec 15 16:35:26 GMT 2023
EMA ASSESSMENT REPORTS EVOTOPIN (WITHDRAWN: OVARIAN NEOPLASMS)
Created by admin on Fri Dec 15 16:35:26 GMT 2023 , Edited by admin on Fri Dec 15 16:35:26 GMT 2023
NCI_THESAURUS C2843
Created by admin on Fri Dec 15 16:35:26 GMT 2023 , Edited by admin on Fri Dec 15 16:35:26 GMT 2023
EMA ASSESSMENT REPORTS TOPOTECAN ACTAVIS (AUTHORIZED: UTERINE CERVICAL NEOPLASMS)
Created by admin on Fri Dec 15 16:35:26 GMT 2023 , Edited by admin on Fri Dec 15 16:35:26 GMT 2023
EU-Orphan Drug EU/3/08/562
Created by admin on Fri Dec 15 16:35:26 GMT 2023 , Edited by admin on Fri Dec 15 16:35:26 GMT 2023
EMA ASSESSMENT REPORTS HYCAMTIN (AUTHORIZED: OVARIAN NEOPLASMS)
Created by admin on Fri Dec 15 16:35:26 GMT 2023 , Edited by admin on Fri Dec 15 16:35:26 GMT 2023
EMA ASSESSMENT REPORTS TOPOTECAN HOSPIRA (AUTHORIZED: UTERINE CERVICAL NEOPLASMS)
Created by admin on Fri Dec 15 16:35:26 GMT 2023 , Edited by admin on Fri Dec 15 16:35:26 GMT 2023
Code System Code Type Description
ChEMBL
CHEMBL84
Created by admin on Fri Dec 15 16:35:26 GMT 2023 , Edited by admin on Fri Dec 15 16:35:26 GMT 2023
PRIMARY
DRUG BANK
DB01030
Created by admin on Fri Dec 15 16:35:26 GMT 2023 , Edited by admin on Fri Dec 15 16:35:26 GMT 2023
PRIMARY
RXCUI
266573
Created by admin on Fri Dec 15 16:35:26 GMT 2023 , Edited by admin on Fri Dec 15 16:35:26 GMT 2023
PRIMARY RxNorm
FDA UNII
956S425ZCY
Created by admin on Fri Dec 15 16:35:26 GMT 2023 , Edited by admin on Fri Dec 15 16:35:26 GMT 2023
PRIMARY
DAILYMED
956S425ZCY
Created by admin on Fri Dec 15 16:35:26 GMT 2023 , Edited by admin on Fri Dec 15 16:35:26 GMT 2023
PRIMARY
PUBCHEM
60699
Created by admin on Fri Dec 15 16:35:26 GMT 2023 , Edited by admin on Fri Dec 15 16:35:26 GMT 2023
PRIMARY
USAN
BB-40
Created by admin on Fri Dec 15 16:35:26 GMT 2023 , Edited by admin on Fri Dec 15 16:35:26 GMT 2023
PRIMARY
RS_ITEM_NUM
1672257
Created by admin on Fri Dec 15 16:35:26 GMT 2023 , Edited by admin on Fri Dec 15 16:35:26 GMT 2023
PRIMARY
CAS
119413-54-6
Created by admin on Fri Dec 15 16:35:26 GMT 2023 , Edited by admin on Fri Dec 15 16:35:26 GMT 2023
PRIMARY
EVMPD
SUB04921MIG
Created by admin on Fri Dec 15 16:35:26 GMT 2023 , Edited by admin on Fri Dec 15 16:35:26 GMT 2023
PRIMARY
NCI_THESAURUS
C2828
Created by admin on Fri Dec 15 16:35:26 GMT 2023 , Edited by admin on Fri Dec 15 16:35:26 GMT 2023
PRIMARY
MERCK INDEX
m10977
Created by admin on Fri Dec 15 16:35:26 GMT 2023 , Edited by admin on Fri Dec 15 16:35:26 GMT 2023
PRIMARY Merck Index
SMS_ID
100000091113
Created by admin on Fri Dec 15 16:35:26 GMT 2023 , Edited by admin on Fri Dec 15 16:35:26 GMT 2023
PRIMARY
EPA CompTox
DTXSID1045952
Created by admin on Fri Dec 15 16:35:26 GMT 2023 , Edited by admin on Fri Dec 15 16:35:26 GMT 2023
PRIMARY
NSC
759263
Created by admin on Fri Dec 15 16:35:26 GMT 2023 , Edited by admin on Fri Dec 15 16:35:26 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE